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Assessment of the new proliferation marker MIB1 in breast carcinoma
using image analysis: associations with other prognostic factors and
survival
SE Pinder', P Wencyk', DM Sibbering2, JA Bell', CW Elston', R Nicholson3, JFR Robertson2,
RW Blamey2 and 10 Ellis'
Departments of 'Histopathology and 2Surgery, The City Hospital, Nottingham; 3The Tenovus Institute, Cardiff, UK.
S_ary The 'growth fraction' of tumours can now be assessed on paraffin sections of tissues using the
monoclonal antibody MIBI by a microwave antigen retnreval technique. The MIBI labelling index was studied
using a CAS 200 image analyser in 177 tumours from women with pnrmary operable breast carcinoma in
whom long-term follow-up data were known. Statistical analysis showed a strong association between the
MIBI labelling index and histological grade (P <0.001), tumour size (P =0.002). tumour type (P <0.001)
and also patient survival (P <0.001). No association with lymph node stage (P = 0.59), local (P = 0.974) or
regional recurrence (P = 0.185), the presence or absence of distant metastases (P = 0.418), patient age
(P = 0.309), menopausal status (P = 0.181) or oestrogen receptor status (P = 0.401) was found in this group
of patients. In multivariate analysis for survival, when histological grade. lymph node stage and tumour size
were included as well as the MIBI labelling index, each was found to be of independent significance. If
histological grade was not included, MIBI replaced it as the most important variable predicting for survival in
this group of patients. The results suggest that the tumour growth fraction, as assessed by the MIBI labelling
index, is an important predictor of survival.
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An assessment of the growth fraction of a tumour may be
performed by immunohistochemical staining of frozen sec-
tion matenral using Ki-67 monoclonal antibody (Gerdes, et
al., 1983, 1984). This reacts with a proliferation-associated
antigen which is expressed in all cells not in Go phase of the
cell cycle. Many authors have produced data suggesting that
an assessment of the percentage of cells showing immunore-
activity with Ki-67 antibody correlates with other methods of
determining the rate of growth of a malignant tumour such
as S-phase fraction assessed by flow cytometry and mitotic
count (Walker and Camplejohn, 1988; Dawson et al., 1990;
Isola et al., 1990; Kennedy et al., 1992), as well as thymidine
labelling index (Karmel et al., 1989) and 5-bromodeoxyuri-
dine labelling (Sasaki et al., 1988). More recently, several
other antibodies have been described which have been advo-
cated as effectively demonstrating proliferating cells in
formalin-fixed tissue including anti-proliferating cell nuclear
antigen (PCNA), Ki-SI and MIBI. MIBI is raised against
recombinant parts of the Ki-67 antigen and can be used on
microwave-processed, paraffin-embedded tissue (Cattoretti et
al., 1992). This antibody appears to be superior to others for
assessing tumour proliferation on routinely fixed and pro-
cessed material not only because of the simplicity of the
technique but because good correlation with Ki-67 expression
on frozen material has also been reported (McCormick et al.,
1993a,b).
In breast carcinomas, although some have found no associ-
ation between Ki-67 immunoreactivity and other prognostic
variables (Stumpp et al., 1992), many authors have reported
an association with histological grade (Walker and Cample-
john, 1988; Betta et al., 1989; Bouzubar et al., 1989; Wrba et
al., 1989; Dawson et al., 1990). Associations with lymph
node status (Wrba et al., 1989), patient's age (Sahin et al.,
1991), tumour size (Wrba et al., 1989; Veronese and Gamba-
corta, 1991), oestrogen and progesterone receptor status
(Wrba et al., 1989; Campani et al., 1991; Di-Stefano et al.,
1991; Veronese and Gambacorta, 1991), ploidy (Dawson et
al., 1990; Isola et al., 1990; Lee et al., 1992), p53 (Barbareschi
et al., 1992) and epidermal growth factor receptor expression
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(Nicholson et al.. 1993) have all been descnrbed. The majonrty
of these authors have found a correlation with some but not
all of these factors. Nicholson et al. (1991) showed that the
response to endocrine therapy of a breast carcinoma was
related to the degree of Ki-67 immunoreactivity, and an
association between Ki-67 staining and both disease-free
interval and survival has been reported (Veronese et al.,
1993). However, few studies have been performed which have
assessed the percentage of tumour cells expressing the Ki-67
antigen from patients with long-term follow-up because of
the difficulty in obtaining sufficient archival frozen tissue.
The aim of this study was to assess immunoreactivity with
the Ki-67-equivalent MIBI monoclonal antibody in a series
of women with primary breast carcinoma in whom long-term
follow-up and information on many other vanrables were
available. Staining was assessed semiobjectively using a Cell
Analysis System (CAS) 200 image analyser (Bacus and
Grace, 1987).
Materials and methods
Patients
Sections from the tumours of 177 women with primary
operable breast carcinoma were assessed. These patients were
all cared for by one surgical team under the supervision of
RW Blamey and had had either wide local excision or simple
mastectomy, with or without local radiotherapy, but had
received no systemic adjuvant treatments. The tumours were
all less than 5 cm in maximum extent and were not deeply
fixed. Lymph node sampling was performed at the time of
initial surgery (Blamey et al., 1980). All patients were fol-
lowed up every 3 months for 24 months, then 6 monthly to 5
years and annually thereafter. The patient's age, menopausal
status and oestrogen receptor status, as assessed by a dextran
charcoal coated technique (Nicholson et al., 1981), were also
known.
Tissue
The maximum dimension of the tumour was measured in the
fresh stage and then confirmed after fixation when multiple
sections were taken for routine processing. The histological.n1 in ht
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grade (Elston and Ellis, 1991) and histological type (Ellis et
al., 1992) were assessed on 2-pm-thick haematoxylin and
eosin-stained sections of each tumour. The same sections of
tumour were also examined for the presence or absence of
vascular invasion (Pinder et al., 1994).
Method
The paraffin sections were applied to triaminopropyltriethoxy-
silane (TESPA)-coated slides and dewaxed, rehydrated and
blocked for endogenous peroxidase activity with hydrogen
peroxide. They were then microwaved in an 800 W Panasonic
microwave for 1Omin on high power and 1Omin on low
(50%) power in 11 of citrate buffer. After cooling by running
under cold water and blocking for non-specific activity with
swine serum, the sections were incubated with the mono-
clonal antibody MIBI (gift from Johannes Gerdes) at a 1:30
dilution for 40 min. The secondary and tertiary layers were
applied as per the Dako streptavidin-biotin complex/
horseradish peroxidase (mouse/rabbit) kit after washing in
Tris-buffered saline. The complex was visualised using
diaminobenzidine and counterstained with ethyl green solu-
tion.
Image analysis
The percentage of the nuclear area showing immunoreactivity
was assessed using the proliferation tissue programme of the
CAS 200 image analyser. This has sensing channels at
620 nm and 500 nm, one of which identifies all the com-
ponents counterstained with ethyl green (i.e. all the nuclei)
and the other identifies the nuclear components stained
immunohistochemically ('nuclear masking'). Any non-tumour
cells such as stromal nuclei are excluded by a 'draw function'
on the image analyser, which enables the operator to exclude
them from the analysis. After assessment of the nuclear area
required to give sufficient precision, 50.000 ptm2 carcinoma
nuclei were selected from each tumour for quantitation.
Fields were selected at random with no bias towards the
most cellular or immunoreactive fields.
Statistical analysis
Recurrence and survival data was determined by life table
analysis (Mantel-Cox). Multivariate analysis (Cox, 1972)
was also performed to determine which of the variables was
of independent significance in predicting for survival. The
B-values in this analysis show how much each factor contri-
butes to the hazard. and the Z-values reflect the significance
of the B-values. A Z-value greater than 1.96 demonstrates
significance at the 5% level in a two-tailed test.
Results
The immunohistochemical staining was of high quality and
easy to interpret. A range of degree of nuclear staining was
seen from weakly positive to very strongly positive nuclei. No
cytoplasmiic reactivity was noted. The range of percentage
nuclear area positivity seen with MIB1 monoclonal antibody
varied from 0.6% to 62.5%. The mean nuclear area showing
immunoreactivity was 27.3% and the median 24.6%.
A statistically significant correlation between the MIBI
labelling index and histological grade (X: = 39.85.
P <0.0001) was seen in univariate analysis when tumours
were placed into three categories based on the percentage of
nuclear immunoreactivity with MIBI monoclonal antibody
around the tertiles (<17%, >17% <34%. >34%) (Table
I). Only one of the 22 (4.6%) carcinomas in the group of
tumours which showed more than 34% nuclear MIBI posi-
tivity was of histological grade 1. compared with 62 of the 99
(62.6%) grade 3 tumours. In addition. MIBI positivity also
showed an association (' = 16.72, P <0.0002) with tumour
type. when tumour type was grouped into four categories
based on prognosis. and a correlation with tumour size
(r2
= 9.23. P <0.002) was also identified.
Univariate analysis showed no association between the
MIBI labelling index and patient's age ( = 3.59.
P = 0.31). oestrogen receptor status (/ = 0.70. P = 0.40) or
menopausal status (r = 1.79. P = 0.18). Nor was any
association with local (/ = <0.01. P = 0.97) or regional
Q' = 1.76, P = 0.19) recurrence seen in this series. No cor-
relation with the presence or absence of distant metastases
( 0.66, P = 0.42) or lymph node stage (X = 1.05.
P = 0.59) was found.
The three categories of MIBI immunoreactivity also
showed a strong association with overall survival (Figure 1).
Those patients with carcinomas which demonstrated less than
17% nuclear area immunoreactivity had a significantly better
survival than those showing 17-34% nuclear positivity. and
those women with a high MIBl labelling index (> 34%) had
the poorest survival.
Multivariate analysis (Table II) including histological
grade. tumour size. lymph node stage and MIBI labelling
Table I Association of MIBI labelling index with histological
grade
MIBI group
<J17% >17%. <34% >34% No. patients
Histological grade
1 16 5 1 22
2 22 23 11 56
3 10 27 62 99
No. of patients 48 55 74 177
Table II Multivariate analysis for survival
B Z
Grade 0.70 3.95
Stage 0.64 5.31
MIBI 0.47 2.04
Size 0.29 2.63
Table 1)1 Multivariate analysis for survival
B Z
Grade - -
Stage 0.60 4.86
MIBI 0.89 4.10
Size 0.32 2.94
.C
cr
Months
Number 48
of 55
patients 74
45 42 35
48 38 29
61 45 35
28
24
30
21
17
24
11
7
11
Figure I Assocation of MIBI labelling index with survival. *.
<17%; *, > 170. < 34%; S. > 34%.
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showed that each of these variables was of independnt
signifince in predicting for survival in this group of
patients. The most important factor, with the highest B-value
(0.70) was histologl grade, with lymph node stage second
in weight with a B-vahle of 0.64. MIBI was the third most
important factor and had more effect than tumour size (B-
values 0.47 and 0.29 respectively). When histological grade
was excluded from the analysis (Table Ill), MIBI positity
replaced it as the most important vanable for sunival, as
shown by the highest B-value (0.89) with stage second (0.60)
and size third (0.32).
The range of nuclear area positivity (0.6-62.5%) seen with
the monoclonal antibody MIBI is similar to the 0-80% we
have reported previously with the Ki-67 antibody (Bouzubar
et al., 1989). The mean (27.3%) and median (24.6%) levels
are, however, somewhat higher than have been recorded with
other methods of determining the degree of positivity of
Ki-67 antibody [median range 6.3% (Isola et al., 1990) to
15% (Barbareschi et al., 1992)1; Dawson et al. (1990), how-
ever, reported a mean Ki-67 positivity of 21.6% in breast
carcinomas using the CAS 100 image analysis system, similar
to the mean value in this series of 27.3%. A range ofdegrees
ofnuclear positivity is seen with MIBI monoclonal antibody,
with some nuclei showing weak positivity. The image
analyser identifies as positive these weakly stained nuclei.
In addition to Ki-67 immunohistochemical assesment,
some authors have found that PCNA immunostai also
shows a sigilcnt relationship with histological grade, histo-
logical type and survival and with tumour rcurrerc (Aal-
tomaa et al., 1992). Although in one study it was reported
that the Ki-67 fraction was invariably higher than the growth
fraction as assesd by bromodeoxyuridine labelling curves
and that non-proliferating cells reained the Ki-67 antigen for
considerable periods of time (Hein van Direndonck et al.,
1989) other authors have su that the Ki-67 antigen is
probably rapidly catabolised at the end of M-phase (McCor-
mick et al., 1993b). McCormick et al. (1993b) suggest that,
because of this, the examination of MIB1 is superior to the
immunohistochemical assessment of other cell proliferation
antigens such as PCNA and Ki-Sl, which are present at low
levels in non-cycling cells.
We demonstrate here similar biological associations with
MIB1 labelling index in primary breast carcinomas to those
described by many groups with S-phase fraction, thymidie
labelling and cell cycle analysis by flow cytometry. The
strong association between the extent ofnuclear area staining
with MIBI antibody and histological grade is similar to that
we have reported previously with Ki-67 (Bouzubar et al.,
1989) and which has been noted by others (Walker and
Camplejohn, 1988; Betta et al., 1989; Wrba et al., 1989;
Dawson et al., 1990). This correlation with histological grade
is strong; however, in multivariate analysis MIBI labellng is
of indepenent prognostic sign . When histological
grade is excuded from the analysis, MIBI positivity replac
it as the factor ofmost importance in predicting for survival.
Thus, the MIBI labelling index and an assnent of histo-
logcal grade appear to be complementary rather than
equvalent prognostic factors.
As in the previous sudy in which Ki-67 immunoreactivity
was assessed on frozen tissue, we found no association
between MIBI positivity and lymph node stage or meno-
pausal or oestrogen receptor status. Other groups have
reported an inverse relationship between the growth fraction
assesd in this way and the oestrogen receptor status of the
tumour. This difference may, in part, relate to different
mehods of determining stage (lymph node sampling or
clearace) and alternative techniques of demonstrating the
oestrogen receptor.
The assessment of MIBI nuclear positivity has many
advantages over other methods of measuring the growth
fraction of tumours, such as flow cytometry. Routinely pro-
cessed material can be examined and special facilities are not
required. In this study we have examined mmunorvity
with MIBI monoclonal antibody by image analysis. This is
semiobjective and requires selection of the cells to be
included by the operator, who excludes non-tumour cells.
Thus the proportion of the nuclear area of the carcinoma
cells showing immunoreactivity is assessd. While this is not
feasible without image analysis, a proliferation index count
can also be produced mathematically from these results, by
incorporating estimates of the nuclear size and the amount of
positive staining within each nucleus. When this was per-
formed, a statistical analyss showed similar findgs to those
ofthe percentage area postivity with a signifiant association
with survival and histological grade. This is supportive
evidenc for the usfulness of the more simple method of
assesing subjectively the percentage of MIBi positivity.
Study of the proliferation index of breast carcinomas by this
simple immunohistochemical method may have a useful role
in predicting the biological behaviour in breast carcinomas
and thus in selcting the optimum treatment option for each
patient The examination of the growth fraction of a tumour
by immunohistochemistry may in the future become routine.
* _~~~~i
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